← Home / GINKGO BIOWORKS HOLDINGS, INC. (DNA)
Stock Analysis
GINKGO BIOWORKS HOLDINGS, INC. (DNA)
DNA
DNA · Market data
8.09 -0.00%
Track DNA in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when DNA price is:
52W Range Position
24%
LOWMIDHIGH
Trend
Vulnerable
Momentum
Neutral
Updated: 2026-08-02 22:33 UTC
WOI Investment Thesis
Vulnerable
Watch confirmation and invalidation levels before acting.
⚖️
✓
Fundamentals
Weak / Negative
✓
Price Structure
Vulnerable
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
—
↗
Break Above
Confirmation improves above resistance.
8.49
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below —
Recent Company Events
SEC VERIFIED
Latest material filings
MAY
7
●
Financial Results
HIGH
Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab
(NYSE: DNA, “Ginkgo”) today announced its results for the first quarter of 2026 that ended March 31, 2026.
8-K Filing • SEC EDGAR
What's Driving DNA?
📈 Technical recovery is improving
Momentum is Neutral. Watch 8.49 for confirmation and — for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
—
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
46.1
Price Chart
DNA — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-31
Cash
Cash-flow pressure
TTM free cash flow is negative. P/FCF and FCF yield should be read with caution.
Market Cap
$498.8M
Company size
EV
$355.0M
Debt-adjusted value
P/E
-1.4
Not meaningful
P/S
3.5
Low sales multiple
P/B
0.8
Low book multiple
EV/Sales
2.5
Low sales multiple
EV/EBIT
-1.2
Not meaningful
P/FCF
-2.9
Not meaningful
FCF Yield
-34.86%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial pressure is elevated
Financial quality is mixed, with cash flow or balance sheet items requiring closer monitoring.
↗
Revenue Growth
Weak
●
Profitability
Negative
≈
Cash Flow
Pressured
⚖
Balance Sheet
Manageable
💵 Revenue
19.47M
↘ Weak
📈 Net Income
-82.59M
↘ Negative
🧮 EPS (Basic)
-1.39
↘ Negative
GINKGO BIOWORKS HOLDINGS, INC.
Related Opportunities